Lavipharm S.A. Stock

LAVI

GRS246003008

Pharmaceuticals

Market Closed - Athens S.E. 10:10:04 2026-09-03 EDT			5-day change	1st Jan Change
1.620 ^EUR	-0.12%		-1.22%	+67.01%

06-24	Lavipharm S.A. announces Annual dividend, payable on July 24, 2026	CI
05-28	Lavipharm Q1 earnings before tax from continuing operations EUR1.41 million, up 28.6% Y/Y	RE

Lavipharm SA is a Greece-based pharmaceutical and healthcare company engaged in the research and development of drug delivery solutions and the commercialisation of pharmaceutical, over-the-counter (OTC) and related healthcare products. It is active in the provision of prescription medicines, OTC products and food supplements, supported by integrated activities across research and development, manufacturing and commercial operations. It maintains a portfolio focused primarily on therapeutic areas including cardiology, central nervous system disorders, urology, oncology and chronic pain, supplying solutions designed for healthcare professionals and patients. The Company operates in both domestic and international markets and combines product development capabilities with market access and distribution activities, while acting as the parent entity of the Lavipharm Group through which its broader operations are conducted.

Employees

285

Sector

Pharmaceuticals

Calendar

09-17 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-09-03	€1.620	-0.12%	24,809
26-09-02	€1.622	-1.10%	85,748
26-09-01	€1.640	-0.49%	36,306
26-08-31	€1.648	+0.37%	13,277
26-08-28	€1.642	+0.12%	32,871

Delayed Quote Athens S.E.

More quotes

Stock Market
Stocks
LAVI Stock

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	277M 322M 260M 238M 443M 30.4B 447M 3.07B 1.2B 15.53B 1.21B 1.18B 50.03B	P/E 2024	14.9x	P/E 2025	27.9x
Enterprise Value	303M 353M 285M 260M 486M 33.33B 490M 3.37B 1.31B 17.03B 1.32B 1.3B 54.85B	EV / Sales 2024	3.07x	EV / Sales 2025	3.04x
Free-Float	39.31%	Yield 2024	2.52%	Yield 2025	-

06-24	Lavipharm S.A. announces Annual dividend, payable on July 24, 2026	CI
05-28	Lavipharm Q1 earnings before tax from continuing operations EUR1.41 million, up 28.6% Y/Y	RE
05-28	Lavipharm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-09	Lavipharm to acquire Durogesic pain patch rights from Janssen for $12.0 million	RE
03-19	Lavipharm SA FY 2025 earnings after tax EUR 6.0 million versus EUR 9.0 million year ago	RE
03-19	Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-17	Lavipharm 9-month net profit down to EUR 3.5 million	RE
25-09-18	Lavipharm H1 adjusted EBITDA at EUR 7.7 million, up 29.4% Y/Y	RE
25-09-17	Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-02	Lavipharm S.A. announces Annual dividend, payable on July 24, 2025	CI
25-05-15	Lavipharm Q1 Net Profit At EUR 1.6 Million, Up 46.8% YoY	RE
25-04-14	Lavipharm And Tikun Olam Europe Launch Joint Telemedicine Company	RE
25-03-19	Lavipharm FY 2024 Earnings After Tax EUR 9.0 Million Versus EUR 1.87 Million Year Ago	RE

09-03	Lavipharm S A : Announcement Appointment of Chief Manufacturing & Operations Officer	PU
06-11	Lavipharm S A : Announcement Appointment of Chief Quality Officer	PU
05-22	Lavipharm S A : IMPORTANT CORPORATE EVENTS	PU
11-07	Lavipharm S A : OTHER ANNOUNCEMENTS	PU
25-10-15	Lavipharm S A : ANNOUNCEMENT OF REGULATED INFORMATION - TRANSACTIONS NOTIFICATION	PU

1 day	-0.12%
1 week	-1.22%
Current month	-1.70%
1 month	-0.12%
3 months	+1.25%
6 months	+41.11%
Current year	+67.01%

1 week	1.59	1.68
1 month	1.53	1.69
Current year	0.94	1.74
1 year	0.76	1.74
3 years	0.58	1.74
5 years	0.35	2.22
10 years	0.16	2.22

Lavipharm S.A. Stock

Stocks

LAVI

GRS246003008

Pharmaceuticals

Valuation : Lavipharm S.A.

Chart: Lavipharm S.A.

Latest news : Lavipharm S.A.

Press Releases : Lavipharm S.A.

Quotes and Performance

Price Extremes

Managers and Directors : Lavipharm S.A.

Latest insider transactions

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Manager	Title	Age	Since
Vassilis Baloumis DFI	Director of Finance/CFO	-	2021-11-30
Ligia Panaitescu CTO	Chief Tech/Sci/R&D Officer	-	-
Eleana Nikolopoulou CMP	Compliance Officer	-	-

Director	Title	Age	Since
Venetsiana-Loukia Lavida BRD	Director/Board Member	-	-
Christos Panagiotis Diamantopoulos BRD	Director/Board Member	76	-
Minas G. Tanes CHM	Chairman	86	2020-12-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/12/25	Vassilis Baloumis	Buy	Chief Financial Officer	20,000	0.0119%
5/27/23	Thomas Tseronis	Sell		35,434	0.0189%
3/28/23	Vassilis Baloumis	Buy	Chief Financial Officer	23,455	0.0125%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LAVIPHARM S.A.	-0.12%	-1.22%	+98.77%	+136.15%	321M
SUN PHARMACEUTICAL INDUSTRIES LTD.	-0.81%	+0.14%	+21.37%	+72.77%	49.06B
OTSUKA HOLDINGS CO., LTD.	-1.06%	-0.49%	+48.26%	+116.95%	40.37B
ZYDUS LIFESCIENCES LIMITED	-0.97%	-3.88%	+13.37%	+86.17%	12.19B
CIPLA LIMITED	-1.28%	-1.78%	-11.64%	+11.99%	12.08B
KRKA, D. D.	+0.57%	-0.56%	+26.56%	+153.11%	9.14B
GEDEON RICHTER	+0.08%	-4.12%	+24.01%	+42.89%	7.36B
GLENMARK PHARMACEUTICALS LIMITED	-0.04%	-0.04%	+22.68%	+224.81%	7.35B
ONO PHARMACEUTICAL CO., LTD.	-1.87%	-0.61%	+40.67%	-12.27%	7.32B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+0.03%	-2.72%	-42.28%	+14.39%	5.19B
Average	-0.55%	-0.40%	+24.18%	+84.70%	15.04B
Weighted average by Cap.	-0.79%	+0.36%	+24.70%	+85.67%

	2024	2025
Net sales	52.95M 61.54M 49.69M 45.46M 84.85M 5.82B 85.52M 588M 229M 2.97B 231M 226M 9.57B	62.58M 72.74M 58.73M 53.73M 100M 6.88B 101M 695M 271M 3.51B 273M 267M 11.32B
Net income	8.98M 10.44M 8.43M 7.71M 14.39M 987M 14.51M 99.71M 38.83M 504M 39.2M 38.35M 1.62B	5.99M 6.96M 5.62M 5.14M 9.59M 658M 9.67M 66.45M 25.88M 336M 26.13M 25.56M 1.08B
Net Debt	28.34M 32.93M 26.59M 24.33M 45.41M 3.11B 45.77M 315M 122M 1.59B 124M 121M 5.12B	26.67M 31M 25.03M 22.9M 42.74M 2.93B 43.08M 296M 115M 1.5B 116M 114M 4.82B